Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises in the divestment of Creuna to Knowit
Mandate

Vinge advises in the divestment of Creuna to Knowit

October 22, 2020 M&A

Vinge advises the seller in the divestment of Creuna to Knowit AB (publ). Creuna is a Nordic digital agency with around 300 employees in Denmark, Norway, Sweden and Finland.

The acquisition is conditional upon the approval from the competition authority in Norway, which is expected to be granted during the fourth quarter of 2020.

Vinge’s team consisted of among others Jonas Bergström, Joacim Rydergård, Johanna Wiberg and Karl Klackenberg.

 

 

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026